Personal Information

Occupation

Chief Science Officer, SENS Foundation

Biography

Dr. Aubrey de Grey is a biomedical gerontologist based in Cambridge, UK, and is the Chief Science Officer of SENS Foundation, a California-based 501(c)(3) charity dedicated to combating the aging process. He is also Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He received his BA and Ph.D. from the University of Cambridge in 1985 and 2000 respectively. His original field was computer science, and he did research in the private sector for six years in the area of software verification before switching to biogerontology in the mid-1990s. His research interests encompass the characterisation of all the accumulating and eventually pathogenic molecular and cellular side-effects of metabolism (“damage”) that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. He has developed a possibly comprehensive plan for such repair, termed Strategies for Engineered Negligible Senescence (SENS), which breaks aging down into seven major classes of damage and identifies detailed approaches to addressing each one. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations.

Dr. de Grey's full CV is available here.

Bookmark

http://www.sens.org

Demographics

Location

Cambridge, UK

History

Member for

2 years 19 weeks

Related content

Publication

• A proposed refinement of the mitochondrial free radical theory of aging.
• Total deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers
• Medical bioremediation: prospects for the application of microbial catabolic diversity to aging and several major age-related diseases.
• The unfortunate influence of the weather on the rate of aging: why human caloric restriction or its emulation may only extend life expectancy by 2-3 years.
• Time to talk SENS: critiquing the immutability of human aging.
• A mechanism proposed to explain the rise in oxidative stress during aging.
• Forces maintaining organellar genomes: is any as strong as genetic code disparity or hydrophobicity?
• Mitochondrial gene therapy: an arena for the biomedical use of inteins.
• Bioremediation meets biomedicine: therapeutic translation of microbial catabolism to the lysosome.
• Appropriating microbial catabolism: a proposal to treat and prevent neurodegeneration.
• Is human aging still mysterious enough to be left only to scientists?
• Escape velocity: why the prospect of extreme human life extension matters now.
• SENS is hard, yes, but not too hard to try: a reply to Warner.
• The Einsteinian Imperative
• Falsifying falsifications: the most critical task of theoreticians in biology.
• Protagonistic pleiotropy: why cancer may be the only pathogenic effect of accumulating nuclear mutations and epimutations in aging.
• Whole-body interdiction of lengthening of telomeres: a proposal for cancer prevention.
• Inter-species therapeutic cloning: the looming problem of mitochondrial DNA and two possible solutions.
• A model of aging as accumulated damage matches observed mortality patterns and predicts the life-extending effects of prospective interventions.
• An engineer's approach to the development of real anti-aging medicine.
• The foreseeability of real anti-aging medicine.
• A strategy for postponing aging indefinitely.
• Aging, elimination of.
• Challenging but essential targets for genuine anti-ageing drugs.
• UK research on the biology of aging -- the next ten years.
• Foreseeable and more distant rejuvenation therapies.
• Like it or not, life extension research extends beyond biogerontology.
• Strategie per un invecchiamento transcurabile ingegnerizzato.
• Defeat of aging - utopia or foreseeable scientific reality?
• Living to 100 and maybe much longer: the engineering and biotechnology of life-extension medicine and when it may arrive.
• Man, machines, manufacturing and maintenance: merits of a much-maligned metaphor.
• Are those 13 proteins really unimportable?
• Response to "approaches and limitations to gene therapy for mitochondrial diseases," Antioxid. Redox Signal. 2001;3:451-460.
• Lysosomal enhancement with microbial hydrolases: a novel strategy for removing protein aggregates.
• Rejuvenating neurons and glia with microbial enzymes.
• Alzheimer's, atherosclerosis, and aggregates: a role for bacterial degradation.
• Foreseeable pharmaceutical repair of age-related extracellular damage.
• The mitochondrial free radical theory of aging.
• The non-correlation between maximum longevity and enzymatic antioxidant levels among homeotherms; implications for retarding human aging.
• The reductive hotspot hypothesis: an update.
• The reductive hotspot hypothesis of mammalian aging: membrane metabolism magnifies mutant mitochondrial mischief.
• Mitochondrial mutations in vertebrate aging.
• Mechanisms underlying the age-related accumulation of mutant mitochondrial DNA.
• Mitochondria in homeotherm aging: will detailed mechanisms consistent with the evidence now receive attention?
• Mitochondrial mutations in mammalian aging: an over-hasty about-turn?
• Reactive oxygen species production in the mitochondrial matrix: implications for the mechanism of mitochondrial mutation accumulation.
• The plasma membrane redox system: a candidate source of aging-related oxidative stress.
• Free radicals in aging: causal complexity and its biomedical implications.
• Gerontologists and the media: the dangers of over-pessimism.
• Antiaging technology and pseudoscience.
• Fear of misrepresentation cannot justify silence about foreseeable life-extension biotechnology.
• The foreseeability of real anti-aging medicine: focusing the debate.
• Biogerontologists' duty to discuss timescales publicly.
• The war on aging.
• La guerra contra el envejecimiento.
• Leon Kass: quite substantially right.
• Three self-evident life-extension truths.
• Aging, childlessness or overpopulation: the future's right to choose.
• Life extension, human rights, and the rational refinement of repugnance.
• Resistance to debate on how to postpone ageing is delaying progress and costing lives.
• When and where to publish important findings: a casualty of biogerontology's rise to respectability.
• "The rate of aging": a counterproductively undefinable term.
• The ethical status of efforts to postpone aging: a reply to Hurlbut.
• The SENS challenge: $20,000 says the foreseeable defeat of aging is not laughable.
• Compression of morbidity: the hype and the reality, part 1.
• Compression of morbidity: the hype and the reality, part 2.
• Has Hippocrates had his day?
• SENS survives the Challenge; now let's get to work.
• Is SENS a farrago?
• The urgency dilemma: is life extension research a temptation or a test?
• The natural biogerontology portfolio: "defeating aging" as a multi-stage ultra-Grand Challenge.
• Aging and airborne HIV: a reassuring analogy.
• Life span extension research and public debate: societal considerations.
• Our right to life.
• Postponing aging: who are the experts?
• Understanding and tackling aging: two fields communicating (a little) at last.
• Old people are people too: why it is our duty to fight aging to the death.
• Is the quest to defeat aging ethical?
• Long live the unreasonable man.
• The singularity and the Methuselarity: similarities and differences.
• More on mitochondria and senescence: Response to Gershon.
• Incorporation of transmembrane hydroxide transport into the chemiosmotic theory.
• Biologists abandon Popper at their peril.
• A proposed mechanism for the lowering of mitochondrial electron leak by caloric restriction.
• UK research on the biology of aging.
• Response to "telomere shortening with aging in human liver".
• HO2*: the forgotten radical.
• Critique of the demographic evidence for "late-life non-senescence".
• A hypothesis for the minimal overall structure of the mammalian plasma membrane redox system.
• Overzealous maximum-likelihood fitting falsely convicts the slope heterogeneity hypothesis.
• Models on trial: falsifying overstated claims of generality does not falsify correctly-stated ones.
• Extrapolaholics Anonymous: why demographers' rejections of a huge rise in cohort life expectancy in this century are overconfident.
• Gene therapy.
• The case for prioritising research on late-onset life-extension interventions in mammals.
• Edmonton: a future center for pioneering biomedical gerontology?
• Calorie restriction, post-reproductive lifespan and programmed aging: a plea for rigor.
• The need to debalkanize gerontology: a case study.
• Curiosity is addictive, and this is not necessarily a good thing.
• Endless Youth.
• Consciousness in the context of radical life extension.
• Aging: A Foreseeable Target of Stem Cells and Regenerative Medicine.
• Persons of Tenure: Less Fortunate Than They May Seem
• Why Are So Many People So Unashamedly Selfish About the Prospect of Combating Aging?
• The Curiously Misunderstood Role of Evidence in Designing New Technology
• Cracks in Social Gerontology's Pro-Aging Edifice
• Cautionary Tales of the Unexpected
• Trans-Simianism and Truthiness: Hints of Progress in the Debate on Whether Aging Is Good
• Combating the Tithonus Error: What Works?
• WILT: necessity, feasibility, affordability
• The Demographic and Biomedical Case for Late-Life Interventions in Aging